Inc. (NASDAQ:INCR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07
|
Submission of Matters to a Vote of Security |
The 2017 Annual Meeting of Stockholders (the Annual Meeting) of
Natural Grocers by Vitamin Cottage, Inc. (the Company) was held
on March 1, 2017, in Lakewood, Colorado. A total of 20,843,668
shares of the Companys common stock were represented at the
Annual Meeting in person or by proxy, constituting approximately
92.83% of the outstanding shares entitled to vote at the Annual
Meeting.
At the Annual Meeting, the Companys stockholders voted on the
following matters, which are described in detail in the Proxy
Statement filed by the Company with the Securities and Exchange
Commission on January 13, 2017:
|
1. |
To elect Zephyr Isely and Michael T. Campbell as Class II |
|
2. |
To ratify the appointment of KPMG LLP (KPMG) as the |
The Companys stockholders approved the nominees recommended for
election in Proposal No. 1. The votes cast on Proposal No. 1 were
as follows:
|
For |
Withheld |
Broker Non-Votes |
||||||||||
|
Zephyr Isely |
17,731,042 | 1,054,724 | 2,057,902 | |||||||||
|
Michael T. Campbell |
18,671,639 | 114,127 | 2,057,902 | |||||||||
The Companys stockholders approved Proposal No. 2. The votes cast
on Proposal No. 2 were as follows:
|
For |
Against |
Abstain |
Broker Non-Votes |
|||||||||||||
|
Appointment of KPMG |
20,816,750 | 21,542 | 5,376 | |||||||||||||
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. Inc. (NASDAQ:INCR) Recent Trading Information
Inc. (NASDAQ:INCR) closed its last trading session up +0.45 at 44.70 with 1,708,691 shares trading hands.
